Key Takeaways
- • QIAGEN reported preliminary Q3 2026 net sales of $548 million, flat at both reported and constant exchange rates (CER), according to Business Wire.
- • Adjusted diluted earnings per share came in at $0.65, also $0.65 at CER.
- • QIAGEN has suspended its full-year 2026 outlook while the announced transaction with EQT Private Equity is pending.
- • QIAGEN will not hold a conference call for Q3 2026 results; full results are scheduled for Wednesday, November 4, 2026.
- • The tender offer for QIAGEN shares, to be made by a bidder affiliated with EQT, has not yet commenced and is subject to BaFin approval and SEC filings.
Summary
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced preliminary third-quarter 2026 financial results, reporting net sales of $548 million at both reported and constant exchange rates. Adjusted diluted earnings per share were $0.65, also unchanged at constant exchange rates.
The company said that, given the announced transaction with EQT Private Equity, it has suspended its full-year 2026 outlook while the deal is pending. QIAGEN also will not hold an earnings conference call for the quarter. Full Q3 2026 results are scheduled for Wednesday, November 4, 2026, at approximately 22:05 Frankfurt time, or 16:05 New York time.
The transaction involves a tender offer by a bidder linked to EQT. According to the release, the offer has not yet commenced. Its terms will be set out in an Offer Document to be published in Germany and filed with the SEC on Schedule TO once BaFin permission is obtained. The offer will be made and implemented under German law, notably the WpÜG, with certain Dutch and U.S. securities law provisions also applicable. QIAGEN intends to file a Schedule 14D-9 with the SEC and to publish a combined recommendation and position statement under German and Dutch rules. The release lists risks including completion timing, the number of shares tendered, possible competing offers, regulatory approvals, and employee and customer retention.
QIAGEN describes itself as a global leader in Sample to Insight solutions, serving more than 500,000 customers across Life Sciences and Molecular Diagnostics. As of September 30, 2026, it employed about 5,400 people across more than 35 locations.
The company said that, given the announced transaction with EQT Private Equity, it has suspended its full-year 2026 outlook while the deal is pending. QIAGEN also will not hold an earnings conference call for the quarter. Full Q3 2026 results are scheduled for Wednesday, November 4, 2026, at approximately 22:05 Frankfurt time, or 16:05 New York time.
The transaction involves a tender offer by a bidder linked to EQT. According to the release, the offer has not yet commenced. Its terms will be set out in an Offer Document to be published in Germany and filed with the SEC on Schedule TO once BaFin permission is obtained. The offer will be made and implemented under German law, notably the WpÜG, with certain Dutch and U.S. securities law provisions also applicable. QIAGEN intends to file a Schedule 14D-9 with the SEC and to publish a combined recommendation and position statement under German and Dutch rules. The release lists risks including completion timing, the number of shares tendered, possible competing offers, regulatory approvals, and employee and customer retention.
QIAGEN describes itself as a global leader in Sample to Insight solutions, serving more than 500,000 customers across Life Sciences and Molecular Diagnostics. As of September 30, 2026, it employed about 5,400 people across more than 35 locations.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.